We propose that PARKIN PD patients and other PD patients with pure nigropathy and lacking synucleinopathy would be ideal candidates for first‐generation dopaminergic cell replacement therapies due to their relatively focal and cell autonomous neurodegeneration. Here, PRKN is linked to synucleinopathy.